An observational study in Lung Cancer, Exercise Capacity and Physical Activity, sponsored by Hasselt University. Completed at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Hasselt University · Observational
This trial investigates the impact of lung cancer treatment on physical status, symptoms and quality of life. Furthermore this trial investigates possible underlying causes and consequences of deconditioning.
Preliminary evidence suggests that patients with lung cancer experience a decrease of exercise tolerance and muscle strength during the course of their treatment. The underlying mechanisms and impact of this change has not yet been investigated. In light of this, our trial will prospectively follow a convenience sample of 150 patients with lung cancer who are undergoing treatment. Patients will be assessed before, during and at the end of the treatment (surgery and/or chemotherapy and/or radiotherapy and/or immunotherapy). The aims of the study are to
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 150 is below the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hasselt University is the lead sponsor of 195 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients with a primary diagnosis of non-small-cell lung cancer who will undergo treatment (surgery, chemotherapy, immunotherapy, radiotherapy, and combination of the previous ones) and score a maximal of 2 on the WHO performance status classification, will be eligible for inclusion.
Healthy matched volunteers will carry out the same assessments once.
Exclusion Criteria:
No study intervention
No study intervention
6MWT
Time frame: Before start of treatment versus 3 months after treatment initiation
1-minute sit to stand test
Time frame: Before start of treatment versus 3 months after treatment initiation
SPPB
Time frame: Before start of treatment versus 3 months after treatment initiation
Handgrip strength
Time frame: Before start of treatment vs. 3 months after treatment initiation
Daily physical activity (self-reported and accelerometer)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months after treatment initiation
Quadriceps strength (isometric and isokinetic)
Time frame: Before start of treatment vs. 3 months after treatment initiation
Respiratory muscle strength (maximal inspiratory and expiratory pressure)
Time frame: Before start of treatment vs. 3 months after treatment initiation
Comorbidities
Time frame: Before start of treatment
Number of hospital admissions
Time frame: 12 months after treatment initiation
All cause and cancer-related mortality
Time frame: 12 months after treatment initiation
Symptoms (Visual analogue scales)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months and 1 year after treatment initiation
Cancer-specific Quality of life (European Organization for the Research and Treatment of Cancer Questionnaire and lung cancer module - EORTC QLQ-C30-LC13)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months an after treatment initiation
General Health Status (12-item Short Form Health Survey - SF-12)
Time frame: Before start of treatment vs. 3 months after treatment initiation
General Health Status (EuroQol 5-dimensions)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 and 1 year months after treatment initiation
Daily functioning (Instrumental Activities of Daily Living Scale - IADLS)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months after treatment initiation
Fatigue (Multidimensional Fatigue Inventory - MFI-20)
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months and 1 year after treatment initiation
Dyspnea (modified medical research council scale - MMRC)
Time frame: Before start of treatment vs.3 months after treatment initiation
Anxiety and depression (Hospital Anxiety and Depression Scale)
Time frame: Before start of treatment vs. 3 months after treatment initiation
Care needs (Care Dependency Scale)
Time frame: Before start of treatment vs. 3 months after treatment initiation
Dyspnea (San Diego Shortness of Breath Questionnaire (SOBQ))
Time frame: Before start of treatment vs. during treatment (surgery: during hospitalization; radio: week 2; chemo: beginning of cycle 2 and cycle 4 (each cycle is 3 weeks); immuno: beginning of cycle 2 and cycle 4) vs. 3 months and 1 year after treatment initiation
Depressive symptomatology (Center for Epidemiologic Studies Depression scale (CES-D))
Time frame: Before start of treatment vs. 3 months after treatment initiation
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hasselt University